The reduced soluble mediator levels in treated MPN patients suggest that drug treatment influenced the production of many soluble mediators, although most of the comparisons did not reach statistical significance—except for G-CSF levels in PV patients. This evidence concerns the gene CSF3 and myeloproliferative disorder.